Vision | Page 31 of 38 | SpiritIndia.com

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

Candidiasis :: Schering-Plough’s NOXAFIL, Posaconazole for Treatment of Oropharyngeal Candidiasis OPC

Schering-Plough Corporation (NYSE: SGP) reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. NOXAFIL is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute.

Herpes :: Merck’s shingles vaccine Zostavax, Zoster Vaccine Live for herpes zoster

Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend that adults 60 years of age and older be vaccinated with ZOSTAVAX? [Zoster Vaccine Live (Oka/Merck)] to help prevent shingles (herpes zoster), a frequently painful disease marked by a blistering rash.

Eyes :: Vitamins, minerals & fish oil can slow progression of vision loss, AMD

UT Southwestern Medical Center is participating in a nationwide study investigating whether modified combinations of vitamins, minerals and fish oil products can slow the progression of vision loss from age-related macular degeneration.

Health :: Learning Katrina?s Lesson – serve the vulnerable in emergencies

On Tuesday and Wednesday of this week, over 150 community leaders and human service providers will come together to strengthen how vulnerable residents are readied for and helped during a disaster. Katrina?s Lesson: Reach Our Vulnerable Residents NOW is one of the first conferences of its kind in King County to unite private and public agencies in this effort.

Health :: NIH Opens Health Information Center at Jackson Medical Mall

The National Institutes of Health opened a new health information center today at the Jackson Medical Mall in Jackson, Mississippi, affirming NIH?s commitment to providing accurate, up-to-date health information to Mississippi residents.

Eyes :: Donning protective glasses clearly key to eye-injury prevention

Accidental eye injury is a leading cause of visual impairment nationally, yet nearly 70 percent of those injured weren’t wearing protective eyewear, the main preventive measure, say ophthalmologists at UT Southwestern Medical Center, say ophthalmologists at UT Southwestern Medical Center.

Eyes :: Receptor that enables clear corneas is identified

The cornea stays clear by expressing a soluble form of a receptor that traps factors enabling growth of vision-obstructing blood vessels, researchers say. When sflt-1, a free-floating receptor for vascular endothelial growth factor A, is eliminated, vision-obstructing blood vessels start growing, teams of researchers led by the Medical College of Georgia and University of Kentucky report in Nature. The paper was published online Oct. 18 and will be in the Oct. 26 print issue.

Eyes :: Bayer & Regeneron’s VEGF Trap for the treatment of eye diseases, AMD

Bayer HealthCare (NYSE: BAY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the companies have entered into a collaboration agreement for the global development, and commercialization outside the U.S., of the VEGF Trap for the treatment of eye disease by local administration (VEGF Trap-Eye). The VEGF Trap-Eye, currently in Phase I and Phase II clinical trials, is a protein that binds to or ?traps? vascular endothelial growth factor (VEGF) and blocks its activity. VEGF is thought to play a critical role in certain eye diseases.

Macular Degeneration :: Evaluating Effect of Antioxidants and Fish Oil on Progression of Age-Related Macular Degeneration (AMD)

The National Institutes of Health (NIH) announces a nationwide study to see if a modified combination of vitamins, minerals, and fish oil can further slow the progression of vision loss from AMD, the leading cause of vision loss in the United States for people over age 60. This new study, called the Age-Related Eye Disease Study 2 (AREDS2), will build upon results from the earlier Age-Related Eye Disease Study (AREDS). The original study results were released five years ago today. The study found that high-dose antioxidant vitamins and minerals (vitamins C and E, beta-carotene, zinc, and copper), taken by mouth, reduced the risk of progression to advanced AMD by 25 percent, and the risk of moderate vision loss by 19 percent.